NCT07140809

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

a Multiple-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib/Ⅱa Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetic Characteristics of JMT202 Injection in Chinese Participants With Hypertriglyceridemia

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia

Conditions

• Hypertriglyceridemia

Interventions

Type	Name	Description
BIOLOGICAL	JMT202 injection	Subcutaneous injection
OTHER	Placebo	Matching Placebo

Timeline

• Start date: 2025-09-09
• Primary completion: 2026-07-31
• Completion: 2026-10-01
• First posted: 2025-08-26
• Last updated: 2025-12-30

Locations

1 site across 1 country: China